Many Chinese advanced equipment teams looking at the U.S. market fall into the same assumption: if the technology is leading, the cost structure is better, and the product is new enough, then the next step should be direct clinical commercialization. It sounds intuitive, but in the U.S. healthcare system...

“We have resources.” That is probably one of the most common statements in cross-border collaboration. The problem is that in healthcare, many real opportunities are not made successful by “having resources” alone. The hardest part is rarely meeting a person, reaching an institution, or arranging a meeting. The ...

Many platform companies face the same problem: as the business expands, outsiders begin to feel that the number of directions is increasing while the logic behind them is becoming less clear. One day the company is doing medical consumables, then research equipment, then AI systems, rapid testing products, health...

Conversations about health AI over the past few years have often centered on a familiar question: Is the model smart enough, is the algorithm advanced enough, and is the accuracy high enough? Today, that conversation is shifting. What increasingly determines whether a health AI product can earn long-term...

Many healthcare technologies historically approached the U.S. market through a familiar sequence: regulatory approval, channel access, customer development, and sales. Once market clearance was secured and a distributor or customer entry point was identified, the market could supposedly open over time. That ...